LUMO Labs makes first TTT.AI pre-seed investment in LUMC innovation partner Autoscriber
LUMO Labs announces a TTT.AI investment in Autoscriber, a Dutch health tech software startup developed in a clinical setting. Autoscriber is developing AI-supported voice recognition software to capture and summarize healthcare professional-patient consultations. TTT.AI is part of the ICAI Venture Program.
Autoscriber’s value proposition is at the intersection of three crucial healthcare trends:
- affordable and accessible healthcare for all
- growing importance of structured/discrete data capture to support data-driven healthcare initiatives
- increasing desire for understanding and self-determination among patients
Health professionals access Autoscriber as a subscription based software-as-a-service (SaaS) solution to large hospitals and practices, smaller practices and General Practitioners. LUMO Labs’ pre-seed funding will allow Autoscriber to go live in multiple hospitals during the next 12 months.
The technology, which promises to streamline clinical interactions into a seamless experience for patients and caregivers, was developed in collaboration with the Clinical Artificial Intelligence and Research Lab (CAIRELab) at Leiden University Medical Center.
“We are very excited to work so closely with the LUMC. Every design choice we make we validate with the physician in a clinical setting.” said Koen Bonenkamp, co-founder and CTO.
Autoscriber software records, transcribes and extracts clinical concepts during consultations. It allows for automated summaries and integration in the patient’s Electronic Health Record that can be easily edited by the physician, providing real-time support for diagnostics and personalized care.
LUMO Labs is investing because Autoscriber meets and/or exceeds their investment fundamentals, including a strong entrepreneurial founding team with profound expertise, proof-of-concept and the promise to dramatically improve the lives of caregivers and patients.
“The problem Autoscriber is solving is universal: reducing time and money spent on repetitive, administrative tasks by physicians while increasing transparency, comprehensibility and human interaction in deeply personal treatment situations,” said LUMO Labs founding partner Andy Lürling. “Their solution is dynamic and highly scalable because of the strong technological and human-centered set-up.”